Reply To: Ocrelizumab – a breakthrough?

December 15, 2021 at 6:28 pm

Perhaps the poster can direct us to the source of the post above stating: “it looks like this drug was approved now by the FDA…”  The only approval(s) I can find are for MS.  Such as this- ” 14 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for OCREVUS® (ocrelizumab), dosed twice-yearly for those living with relapsing or primary progressive multiple sclerosis (MS) who have not experienced any prior serious infusion reactions (IRs). .”